H1 20: soft guidance takes centre stage
14/08/20 -"Novozymes reported largely in line Q2 20 numbers as sales were down 2% (in line with the trading update) and the EBIT margin came in at 25.9% (-10bp vs trading update). The key takeaway was the ..."
Pages
51
Language
English
Published on
14/08/20
You may also be interested by these reports :
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...
27/01/26
Critical USA size increase with value-accretive capacity acquisition
20/01/26
Virbac ended 2025 on a strong note, with sales growth (at CERS) exceeding the management’s guidance that was upgraded only in October 2025. The ...